Patient Characteristics
| Characteristic (n = 50) | Median or absolute number |
| Age (y) | 70 (49–83) |
| Indication, lesion validation, and PSA (ng/mL) | |
| Primary diagnosis | 10 (20%) |
| Validation by histopathology | 10 of 10 (100%) |
| PSA | 31.8 (2.1–167.0) |
| Biochemical persistence after primary surgery | 5 (10%) |
| Validation by histopathology | 5 of 5 (100%) |
| PSA | 1.1 (0.4–2.2) |
| Biochemical recurrence | 25 (50%) |
| Validation by histopathology | 10 of 25 (40%) |
| Validation by post-EBRT follow-up | 15 of 25 (60%) |
| PSA | 0.9 (0.2–26.3) |
| Staging of metastatic disease | 10 (20%) |
| Validation by 68Ga-PSMA-11 PET/CT follow-up | 10 of 10 (100%) |
| PSA | 71.9 (0.9–9237.0) |
| Tumor stage | |
| 68Ga-PSMA-11 PET/CT positive for prostate cancer | 44 (88%) |
| Local tumor | 9 (18%) |
| N positive | 30 (60%) |
| Mb positive | 15 (30%) |
| Mc positive | 6 (12%) |
EBRT = external-beam radiation therapy.
Data are median, with range in parentheses, or absolute number, with percentages in parentheses.